McKesson (NYSE:MCK) Updates FY 2025 Earnings Guidance

McKesson (NYSE:MCK - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 31.750-32.550 for the period, compared to the consensus estimate of 32.190. The company issued revenue guidance of -.

Analysts Set New Price Targets

MCK has been the subject of several recent analyst reports. Wells Fargo & Company dropped their price objective on shares of McKesson from $576.00 to $535.00 and set an equal weight rating for the company in a report on Friday, September 13th. Bank of America lifted their price objective on McKesson from $590.00 to $670.00 and gave the company a buy rating in a research report on Tuesday, June 25th. Leerink Partners decreased their target price on McKesson from $670.00 to $665.00 and set an outperform rating on the stock in a report on Thursday, September 5th. JPMorgan Chase & Co. upped their price target on shares of McKesson from $656.00 to $661.00 and gave the stock an overweight rating in a research report on Wednesday, August 21st. Finally, Evercore ISI decreased their price objective on shares of McKesson from $660.00 to $630.00 and set an outperform rating on the stock in a report on Thursday, August 8th. Four analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of Moderate Buy and a consensus target price of $613.36.

McKesson Stock Down 0.0 %

Shares of MCK traded down $0.09 during trading hours on Thursday, reaching $479.05. The stock had a trading volume of 1,161,781 shares, compared to its average volume of 800,293. The company has a market cap of $62.12 billion, a P/E ratio of 21.48, a P/E/G ratio of 1.18 and a beta of 0.44. McKesson has a 52 week low of $431.35 and a 52 week high of $637.51. The firm has a 50-day moving average of $554.66 and a 200 day moving average of $556.20.

McKesson (NYSE:MCK - Get Free Report) last announced its quarterly earnings results on Wednesday, August 7th. The company reported $7.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.21 by $0.67. McKesson had a negative return on equity of 242.57% and a net margin of 0.94%. The company had revenue of $79.28 billion during the quarter, compared to the consensus estimate of $82.53 billion. During the same period in the prior year, the company earned $7.27 earnings per share. The company's revenue for the quarter was up 6.4% compared to the same quarter last year. As a group, equities analysts expect that McKesson will post 32.07 earnings per share for the current year.

McKesson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 1st. Stockholders of record on Monday, September 2nd will be paid a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 0.59%. This is an increase from McKesson's previous quarterly dividend of $0.62. The ex-dividend date of this dividend is Friday, August 30th. McKesson's dividend payout ratio is currently 12.69%.

Insider Buying and Selling

In related news, CEO Brian S. Tyler sold 3,753 shares of McKesson stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $561.10, for a total transaction of $2,105,808.30. Following the completion of the transaction, the chief executive officer now owns 78,586 shares in the company, valued at $44,094,604.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last quarter, insiders have sold 11,259 shares of company stock worth $6,635,492. Corporate insiders own 0.11% of the company's stock.

About McKesson

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.